Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation.

Jain A, Motatis AKB, Dharmashekar C, Shreevatsa B, Vs S, Srinivas M, Srinivasa SM, P A, Prasad MNN, Rosell R, Codony-Servat J, Rangappa S, Iqbal M, Abass KS, Amachawadi RG, Stupin V, Kollur SP, Shivamallu C, Silina E

Open source

DOI: 10.3389/fonc.2025.1645905
Published: 2025
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2025.1645905,
  title = {Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation.},
  author = {Jain A and Motatis AKB and Dharmashekar C and Shreevatsa B and Vs S and Srinivas M and Srinivasa SM and P A and Prasad MNN and Rosell R and Codony-Servat J and Rangappa S and Iqbal M and Abass KS and Amachawadi RG and Stupin V and Kollur SP and Shivamallu C and Silina E},
  year = {2025},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2025.1645905},
  url = {https://doi.org/10.3389/fonc.2025.1645905}
}

RIS

TY  - JOUR
TI  - Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation.
AU  - Jain A
AU  - Motatis AKB
AU  - Dharmashekar C
AU  - Shreevatsa B
AU  - Vs S
AU  - Srinivas M
AU  - Srinivasa SM
AU  - P A
AU  - Prasad MNN
AU  - Rosell R
AU  - Codony-Servat J
AU  - Rangappa S
AU  - Iqbal M
AU  - Abass KS
AU  - Amachawadi RG
AU  - Stupin V
AU  - Kollur SP
AU  - Shivamallu C
AU  - Silina E
PY  - 2025
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2025.1645905
UR  - https://doi.org/10.3389/fonc.2025.1645905
ER  -

APA

A, J., AKB, M., C, D., B, S., S, V., M, S., SM, S., A, P., MNN, P., R, R., J, C., S, R., M, I., KS, A., RG, A., V, S., SP, K., C, S., & E, S. (2025). Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation.. Frontiers in oncology. https://doi.org/10.3389/fonc.2025.1645905

Source records

pubmed · retrieved 2026-09-27T08:50:55.708Z